The director of the Alzheimer’s Disease Research Center at Mayo Clinic detailed the current issues with access and affordability to critical biomarkers in the screening and monitoring of patients in Alzheimer disease trials. [WATCH TIME: 3 minutes]
Ronald C. Petersen, MD, PhD
Advertisement
Articles by Ronald C. Petersen, MD, PhD
The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided perspective on the emergence in antiamyloid therapies, assessing clinically meaningful benefit, and potential changes to trial design in the future. [WATCH TIME: 3 minutes]
Gaining a Better Understanding of Clinical Benefit in Alzheimer Disease: Ronald C. Petersen, MD, PhD
The director of the Alzheimer’s Disease Research Center at Mayo Clinic discussed a recently published paper focused on the expectations and clinical meaningfulness of randomized controlled trials in Alzheimer disease. [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
Gaining a Better Understanding of Clinical Benefit in Alzheimer Disease: Ronald C. Petersen, MD, PhDPublished: February 9th 2023 | Updated:
Lessons Learned About Clinically Meaningful Benefit from Antiamyloid Trials: Ronald C. Petersen, MD, PhDPublished: February 12th 2023 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
A Step Forward in Multiple System Atrophy: Phase 2 Findings Reinforce ATH434’s Disease-Modifying Potential
2
NeuroVoices: Gerald Maguire, MD, on Raising Awareness of the Neurobiology of Stuttering
3
Earlier Initiation of Pimavanserin Leads to Better Improvement of Parkinson Disease Psychosis Symptoms
4
Incorporating AI Into Stroke Triage
5
